Fig. 1
From: Multi-pathway targeted therapy of MASH-HCC using miR-22
miR-22 treats MASH-HCC. A Study design for miR-22 treatment in MASH/HCC. Three-week-old male mice were fed a Western Diet (WD) for 3 months, followed by hydrodynamic injection of Myr-AKT1 and NRasV12 (AKT/RAS) with Sleeping Beauty transposase. 1 week later, AAV8-miR-22 or AAV8 blank control (5 × 1012 GC/kg) was administered intravenously. Mice were maintained on a WD during the entire experiment. B liver-to-body weight (L/B) ratio, C representative liver morphology, H&E, and Sirus red-stained liver sections. Fibrosis was quantified in Sirius Red-stained liver sections and analyzed using ImageJ software. Images were converted to 8-bit grayscale, and a consistent threshold was applied to quantify collagen-positive areas as a percentage of the total tissue area. Results were averaged across fields for each sample. D hepatic mRNA levels of Afp, Ccna2, Gpc3, and Lgals1. Data represent mean ± SD (n = 6–8/group). p < 0.05, ∗ p < 0.01, ∗ ∗ p < 0.001 by one-way ANOVA